Ropes & Gray Represents Teva in Partnership With Samsung Bioepis to Commercialize Rare Disease Biosimilar in U.S.
January 18, 2025
January 18, 2025
BOSTON, Massachusetts, Jan. 18 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Teva Pharmaceutical Industries in a license, development and commercialization agreement with Samsung Bioepis for rare disease therapy EPYSQLI, the biosimilar to Solirisi in the U.S. The deal was announced on January 10. Financial terms were not disclosed.
Under the agreement, Samsung Biopis will be responsible for the development, regulatory registratio . . .
Ropes & Gray represented Teva Pharmaceutical Industries in a license, development and commercialization agreement with Samsung Bioepis for rare disease therapy EPYSQLI, the biosimilar to Solirisi in the U.S. The deal was announced on January 10. Financial terms were not disclosed.
Under the agreement, Samsung Biopis will be responsible for the development, regulatory registratio . . .